ANGO -20.40% NVDA -0.80% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
AngioDynamics (NASDAQ:ANGO) stock, maker of such medical devices as the NanoKnife tool for "electrocuting" cancer cells, as well as multiple devices for treating peripheral vascular disease, tumbled 20.7% through 10:20 a.m. ET Thursday despite beating analyst forecasts for Q1 earnings this morning.
Heading into the fiscal Q1 2027 report, analysts expected AngioDynamics to lose $0.11 per share on sales of $80.5 million. Instead, AngioDynamics reported only a $0.04 per share loss, and sales were $80.9 million.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
First off, while AngioDynamics beat analyst revenue targets, its year-over-year growth was just 6.9%. More importantly, the earnings "beat" -- the $0.04 loss -- was only a pro forma number. When calculated under generally accepted accounting principles (GAAP), AngioDynamics actually lost $0.17 per share. Admittedly, this was less than the $0.24 per share AngioDynamics lost in fiscal Q1 2026. It's still four times as big a loss as the headline figure.
In other news, AngioDynamics named Eric Honroth, currently the Global President of Life Science at Swedish med-tech company Getinge, to replace Jim Clemmer as CEO.
Honroth inherits a company with a debt-free balance sheet and $34 million in cash -- but also a company that's reported nothing but losses since 2020, and one that isn't expected to turn profitable again before 2029, according to analysts polled by S&P Global Market Intelligence.
In fiscal 2027, AngioDynamics has guided investors to expect $336 million to $341 million in sales, pro forma losses between $0.24 and $0.29 per share -- and probably GAAP losses even bigger, if Q1 is any guide.
Any investor hoping for a quick turnaround at AngioDynamics stock is probably hoping in vain.
Before you buy stock in AngioDynamics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AngioDynamics wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $375,887!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,459,146!*
That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.
*Stock Advisor returns as of October 8, 2026.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Why AngioDynamics Crashed Today was originally published by The Motley Fool
